Cargando…

Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications

Clostridioides difficile infections (CDI) are a leading cause of healthcare-associated infections with a high relapse rate. Current treatment guidelines recommend fidaxomicin as the primary therapy for initial CDI episodes and suggest alternative approaches for recurrent episodes, including fecal mi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Nityanand, Umar, Tungki Pratama, Fahner, Anne-Fleur, Gibietis, Valdis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Commentaries and Views
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337487/ https://www.ncbi.nlm.nih.gov/pubmed/37431860 http://dx.doi.org/10.1080/19490976.2023.2232137

Ejemplares similares

Debunking the myth of using “quiet” in clinical departments: an integrative overview of available literature
por: Umar, Tungki Pratama, et al.
Publicado: (2022)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Uncovering the Harms of Treating Clostridioides difficile Colonization
por: Polage, Christopher R., et al.
Publicado: (2021)

The cytotoxic synergy between Clostridioides difficile toxin B and proinflammatory cytokines: an unholy alliance favoring the onset of Clostridioides difficile infection and relapses
por: Bassotti, Gabrio, et al.
Publicado: (2020)

Monkeypox, smallpox, FDA, and accelerated approval of vaccines – A regulatory perspective
por: Sun, Wellington
Publicado: (2023)

Clinical studies involving probiotics: When FDA’s investigational new drug rubric applies—and when it may not
por: Degnan, Fred H.
Publicado: (2012)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Epidural Abscesses as a Complication of Interleukin-6 Inhibitor and Dexamethasone Treatment in a Patient with COVID-19 Pneumonia: A Case Report
por: Ģībietis, Valdis
Publicado: (2023)

Expanding our grasp of two-component signaling in Clostridioides difficile
por: Berumen Alvarez, Orlando, et al.
Publicado: (2023)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer
por: Powell, Kerrington, et al.
Publicado: (2021)

The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point
por: Eiser, Arnold R.
Publicado: (2021)

Gut metabolites predict Clostridioides difficile recurrence
por: Dawkins, Jennifer J., et al.
Publicado: (2022)

Characterization of Clostridioides difficile Isolates Available through the CDC & FDA Antibiotic Resistance Isolate Bank
por: Paulick, Ashley, et al.
Publicado: (2021)

Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs
por: Van Norman, Gail A.
Publicado: (2016)

Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
por: Gandy, Sam, et al.
Publicado: (2021)

Screening of Natural Products and Approved Oncology Drug Libraries for Activity against Clostridioides difficile
por: Pal, Rusha, et al.
Publicado: (2020)

Clostridioides difficile Infection in Chronic Kidney Disease—An Overview for Clinicians
por: Dudzicz, Sylwia, et al.
Publicado: (2021)

Host and Clostridioides difficile-Response Modulated by Micronutrients and Glutamine: An Overview
por: Loureiro, Andréa V., et al.
Publicado: (2022)

Teaching old mice new tricks: the utility of aged mouse models of C. difficile infection to study pathogenesis and rejuvenate immune response
por: Shin, Jae Hyun, et al.
Publicado: (2021)

Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
por: Allegretti, Matteo, et al.
Publicado: (2018)

Risk Factors Associated with Recurrent Clostridioides difficile Infection
por: Negrut, Nicoleta, et al.
Publicado: (2020)

Epidemiology of community-acquired and recurrent Clostridioides difficile infection
por: Fu, Yichun, et al.
Publicado: (2021)

400. Rehospitalization of Patients for Recurrent Clostridioides difficile Infection
por: Drwiega, Emily, et al.
Publicado: (2022)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Navigating the 2021 update to the IDSA/SHEA Clostridioides difficile guidelines: An ethical approach to equitable patient care
por: Shoff, Christopher J., et al.
Publicado: (2022)

The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660
por: Orenstein, Robert
Publicado: (2022)

A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways
por: Klein, Kevin, et al.
Publicado: (2021)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use
por: Benedetto Tiz, Davide, et al.
Publicado: (2022)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

Pet Ownership Protects Against Recurrence of Clostridioides difficile Infection
por: Redding, Laurel E, et al.
Publicado: (2020)

Virulence Factors of Clostridioides (Clostridium) difficile Linked to Recurrent Infections
por: Tijerina-Rodríguez, Laura, et al.
Publicado: (2019)

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)

Review of the Impact of Biofilm Formation on Recurrent Clostridioides difficile Infection
por: Rubio-Mendoza, Daira, et al.
Publicado: (2023)

Pseudomembranes on colostomy in a patient with recurrent Clostridioides difficile infection
por: Ueda, Hideki, et al.
Publicado: (2023)

Microbiota in Clostridioides difficile-Associated Diarrhea: Comparison in Recurrent and Non-Recurrent Infections
por: Gazzola, Alessandra, et al.
Publicado: (2020)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qhni2rlkbt6l6etae726j6dt8q